



Marksans Pharma Ltd.

Date: 6th August, 2018

BSE Limited

Corporate Relation Department
Phiroze Jeejeeboi Towers,
Dalal Street,
Mumbai – 400001.
Scrip Code: 524404

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai – 400051.
Symbol: MARKSANS

Sub: News Release

Dear Sir,

Enclosed herewith kindly find a News Release dated 6th August, 2018 of the Company.

You are requested to note the above in your records.

Thanking you.

Yours faithfully,

For **Marksans Pharma Limited**

Harshavardhan Panigrahi
Company Secretary & Manager – Legal



NEWS RELEASE

06th August 2018, Mumbai - India

Marksans Pharma Ltd.

Performance Highlights- Consolidated Q1 2018-19

Marksans Consolidated Revenue at Rs. 238.48 crores in Q1 of FY 2018-19

- EBITDA was **Rs. 38.72** crores for the quarter as compared to Rs.29.03 crores in the previous year same quarter registering growth of **33.38%**.
- Consolidated EBITDA was **16.23%** of Revenue.
- Profit before Tax was Rs. 30.36 crores for the quarter.
- PAT at Rs. **25.14** crores for the quarter as compared to 13.64 crores in the previous year same quarter registering growth of **84.31%**.

Management Discussion and Analysis for the Q1 of FY 2018-19

Revenue Figures – Consolidated

	INR in crores			
	Quarter ended June 2018			
	Q1 FY 2018-19	Q1 FY 2017-18	Growth %	Mix %
Europe, UK – Formulations	108.24	104.31	3.77%	45.38%
US & North America – Formulations	92.08	86.86	6.01%	38.61%
Australia & NZ – Formulations	25.37	23.52	7.87%	10.64%
Rest of World(ROW)	12.80	6.40	100.00%	5.37%
Consolidated Revenue from operations	238.49	221.09	7.87%	100.00%

Business Highlights

- Company achieved revenue of Rs. 108.24 crores from Europe, UK Formulation business as compared to Rs. 104.31 crores achieved during last year same period Registering 3.77% growth during the quarter.
- US & North America Formulation business reported growth of 6.01% to Rs. 92.08 crores during the quarter. Time Cap Laboratories Inc (company's 100% Wholly Owned Subsidiary) offers Marksans an ideal platform to further expand its operations in US.
- Australia & NZ Formulation business revenue was at Rs. 25.37 crores for the quarter registering growth of 7.87% over June quarter in previous year.
- Rest of World Formulation business was Rs. 12.80 crores. Almost 94.63% of company's total revenue came from regulated markets of US, Europe, Australia & New Zealand.

CIN : L24110MH1992PLC066364

Aanish



www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com



Marksans Pharma Ltd.

About Marksans Pharma Limited

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterologicals and Anti-allergies. The company is marketing these products globally.

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Marksans may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Marksans Pharma Limited
11th Floor, "GRANDEUR", Veera desai Extension Road,
Oshiwara, Andheri – (West), Mumbai – 400 053, India
Tel:- +91 22 4001 2000, Fax:- +91 22 4001 2011.

